Part 314 - New Drug Application (NDA)

Part 314 of Title 21 CFR governs the New Drug Application process, specifying the content, format and evidentiary standards required for manufacturers to obtain FDA approval of a drug. It details submission procedures, review timelines, labeling requirements, safety and efficacy data expectations, and post-approval obligations such as reporting and inspections.